Anti-PD-1/IL-15 Fusion Protein JMT108 clinical trials
Also written JMT108.
Its developmentBy CSPC Pharmaceutical Group and Conjupro Biotherapeutics, step by step6 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-PD-1/IL-15 Fusion Protein JMT108 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-PD-1/IL-15 Fusion Protein JMT108 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- JMT108
- 3
Studies by the year they started
6 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Shanghai JMT-Bio Inc. (3) · CSPC Megalith Biopharmaceutical Co.,Ltd. (2) · Conjupro Biotherapeutics, Inc. (1)
Often tested with
Tested in the same studies.
Bevacizumab (1) · Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 (1) · Sintilimab (1) · Modified FOLFOX6 Regimen (1) · Regorafenib (1) · FOLFOXIRI Regimen (1) · Anti-EGFR Antibody-drug Conjugate CPO301 (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Anti-PD-1/IL-15 Fusion Protein JMT108.
- Nov 2026Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract TumorsPhase 1/2 · Shanghai JMT-Bio Inc.
Studies
Open first, then newest update. How each study uses Anti-PD-1/IL-15 Fusion Protein JMT108 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract TumorsRecruitingPhase 1/2Shanghai JMT-Bio Inc.NCT07280832Written as JMT108
- Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular CarcinomaNot yet recruitingPhase 1/2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07761286Written as SYS6090 Injection + Bevacizumab Injection
- A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal CancerNot yet recruitingPhase 1/2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07750041Written as SYS6090 (Fixed Dose Level A) + bevacizumab
- SYS6090 Combination Therapy in Advanced Lung CancerNot yet recruitingPhase 1/2Shanghai JMT-Bio Inc.NCT07472647Written as SYS6090 + pemetrexed + platinum-based chemotherapy
- First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant TumorsRecruitingPhase 1/2Shanghai JMT-Bio Inc.NCT06877650Written as JMT108
- A Phase 1 Study of JMT108 in Participants With Advanced Solid TumorsRecruitingPhase 1Conjupro Biotherapeutics, Inc.NCT07317505Written as JMT108